Neurotech International Ltd (ASX:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18

Recommended

SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.

Franco Granda | 11 March 2026

Fiercer competition expected to squeeze margins.

Shane Ponraj, CFA | 11 March 2026

This ASX share is 84% overvalued and lacks a sustainable competitive advantage.

Shaun Ler | 10 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,976.80	20.70	0.23%
CAC 40	8,041.81	48.32	0.60%
DAX 40	23,640.03	328.60	-1.37%
Dow JONES (US)	47,417.27	289.24	-0.61%
FTSE 100	10,353.77	58.47	-0.56%
HKSE	25,898.76	61.14	-0.24%
NASDAQ	22,716.13	19.03	0.08%
Nikkei 225	55,025.37	776.98	1.43%
NZX 50 Index	13,274.73	18.40	-0.14%
S&P 500	6,775.80	5.68	-0.08%
S&P/ASX 200	8,743.50	19.40	0.22%
SSE Composite Index	4,133.43	10.29	0.25%